Aliskiren Hemifumarate 173334-57-1

inquire about Aliskiren Hemifumarate
Aliskiren Hemifumarate Aliskiren (INN) (trade names Tekturna, U.S.; Rasilez, U.K. and elsewhere) is the first in a class of drugs called direct renin inhibitor. Its current licensed indication is primary (previously essential) hypertension.

Systematic (IUPAC) name: (2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-8-methyl-2-(propan-2-yl)nonanamide
Aliskiren Hemifumarate CAS number: 173334-57-1
ATC code: C09XA02,C09XA52
PubChem: 5493444
DrugBank:
Formula: C30H53N3O6
Molecular mass: 551.758 g/mol
Aliskiren Hemifumarate Assay/Purity: Typically NLT 98%
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.